Relatively limited literature exists on histone modifications, with one notable example being the capacity of NRF2 to facilitate rapid cell proliferation in EZH2 (enhancer of zeste homolog 2)-deficient lung cancer cells, which potentially contributes to therapeutic resistance. This evidence concerns the gene NFE2L2 and lung cancer.